敗血症における免疫機能障害の評価
Sepsis leads to sustained immune system dysfunction resulting in increased susceptibility to secondary infection while in the hospital or after discharge. Consequently, many of the ~2 million Americans that develop sepsis every year will end up back in the ICU, weeks and months later. The objective of this study is to define the cellular and molecular mechanisms driving the dysfunction and reprogramming of T cells and B cells that mediate cellular and humoral immunity using a combination of phenotypic, functional, genomic, and metabolomic assays.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Mrunmayi Tilak
- 電話番号:612-624-9990
- メール:mtilak@umn.edu
研究場所
-
-
Minnesota
-
Minneapolis、Minnesota、アメリカ、55455
- 募集
- University of Minnesota
-
コンタクト:
- Kristine Kancans
- メール:kanca008@umn.edu
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Patients with and without sepsis in the ICU, compared to healthy volunteers
説明
ICU With Sepsis Inclusion Criteria:
-
Age ≥ 18
-
Presumed diagnosis of sepsis, defined as "patients with life-threatening organ dysfunction caused by a dysregulated host response to infection"
-
Patients in the ICU who meet 2 or more of the quick SOFA (qSOFA) definition along with organ dysfunction:
- Respiration rate ≥ 22 breaths/min and/or mechanically ventilated
- An alteration in mental status
- Systolic blood pressure of less than 100 mm Hg and/or receiving inotropes to maintain blood pressure AND/OR
- An acute change in SOFA score ≥2 points, consequent to the infection (can assume SOFA score = 0 in patients with no pre-existing organ dysfunction)
ICU Without Sepsis Inclusion Criteria:
- Age ≥ 18
- Patients requiring care at a M Health Fairview ICU due to high acuity of illness and no other evidence of sepsis
Healthy Volunteer Inclusion Criteria
- Age greater or equal to 18
- ASA status 1, 2 or 3
- May include patients who are receiving dialysis in an outpatient setting
Exclusion Criteria (all groups):
- Active cancer with chemotherapy and/or radiation treatment within the past 6 weeks
- Medication usage that includes immunosuppressive drugs, biologic agents, cytokines, growth factor and interleukins
- Steroid medication usage of > 300mg hydrocortisone per day (equivalent of > 20mg prednisone). Patients with chronic steroid use will be excluded, however patients who have had stress dose steroids administered following admission will be included.
- Patients with a history of, or who currently have evidence of autoimmune disease, including but not limited to: myasthenia gravis, Guillain Barré syndrome, systemic lupus erythematosus, multiple sclerosis, scleroderma, ulcerative colitis, Crohn's disease, autoimmune hepatitis, Wegener's granulomatosis, HIV/AIDS, etc.
- Patients with active or a history of acute or chronic lymphocytic leukemia
- Known history of chronic hepatitis B (HBV) infection and not on treatment with HBV nucleoside analogues prior to the current hospitalization, or HBV DNA > 100 IU/mL
- Known history of infection with hepatitis C (HCV) and currently undergoing treatment for HCV infection or has detectable HCV RNA
- Participation in another investigational interventional drug study within the past 4 weeks
- Current pregnancy
- Current incarceration
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:CASE_CONTROL
- 時間の展望:PROSPECTIVE
グループ/コホートの数
コホートと介入
グループ/コホートグループ/コホート |
介入・治療介入・治療 |
|---|---|
|
健康ボランティア
|
No intervention is included in this study |
|
敗血症のICU患者
|
No intervention is included in this study |
|
敗血症のないICU患者
|
No intervention is included in this study |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
EliSpot - Day 1
時間枠:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
EliSpot - Day 4
時間枠:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
EliSpot - Day 7
時間枠:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
EliSpot - Day 14
時間枠:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
EliSpot - Day 21
時間枠:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
EliSpot - Day 28
時間枠:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Ex Vivo TNF Production - Day 1
時間枠:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Ex Vivo TNF Production - Day 4
時間枠:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Ex Vivo TNF Production - Day 7
時間枠:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Ex Vivo TNF Production - Day 14
時間枠:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Ex Vivo TNF Production - Day 21
時間枠:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Ex Vivo TNF Production - Day 28
時間枠:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 1
時間枠:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 4
時間枠:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 7
時間枠:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 14
時間枠:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 21
時間枠:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Flow Cytometry of Peripheral Blood Leukocytes - Day 28
時間枠:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Cytokines in Serum - Day 1
時間枠:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Cytokines in Serum - Day 4
時間枠:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Cytokines in Serum - Day 7
時間枠:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Cytokines in Serum - Day 14
時間枠:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Cytokines in Serum - Day 21
時間枠:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Cytokines in Serum - Day 28
時間枠:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Quantification of Chemokines in Serum - Day 1
時間枠:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Quantification of Chemokines in Serum - Day 4
時間枠:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Quantification of Chemokines in Serum - Day 7
時間枠:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Quantification of Chemokines in Serum - Day 14
時間枠:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Quantification of Chemokines in Serum - Day 21
時間枠:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Quantification of Chemokines in Serum - Day 28
時間枠:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
Transcriptional Profiling - Day 1
時間枠:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
Transcriptional Profiling - Day 4
時間枠:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
Transcriptional Profiling - Day 7
時間枠:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
Transcriptional Profiling - Day 14
時間枠:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
Transcriptional Profiling - Day 21
時間枠:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
Transcriptional Profiling - Day 28
時間枠:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
|
CBC - Day 1
時間枠:Day 1
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 1
|
|
CBC - Day 4
時間枠:Day 4
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 4
|
|
CBC - Day 7
時間枠:Day 7
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 7
|
|
CBC - Day 14
時間枠:Day 14
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 14
|
|
CBC - Day 21
時間枠:Day 21
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 21
|
|
CBC - Day 28
時間枠:Day 28
|
Sample analysis to determine waxing and waning of Course of Sepsis parameters associated with clinical outcomes |
Day 28
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Thomas Griffith, PhD、University of Minnesota
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- URO-2025-34202
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。